Questions? +1 (202) 540-8337 Login
Trusted News Since 1995
A service for global professionals · Sunday, May 27, 2018 · 448,909,784 Articles · 3+ Million Readers

Amarantus BioSciences Releases New Video Interview with President and CEO Gerald Commissiong

/EINPresswire.com/ Amarantus BioSciences Inc. (OTCBB: AMBS) is a biopharmaceutical company that has discovered a revolutionary therapeutic protein that could change the way many major diseases are treated. Recently, the biotech company released a video interview with its CEO, Gerald Commissiong that covers its development of MANF. Unlike Insmed Inc. (NASDAQ:INSM) or Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), MANF works by reversing the properties of cell apoptosis, which has shown strong signs of efficacy in a wide range of conditions. Recently, the company updated shareholders on its expanded corporate strategy and execution.

Amarantus BioSciences, Inc. released news on January 3, 2012 providing shareholders with an update on the execution of its expanded corporate strategy first announced on November 1st 2011 to position Amarantus as a neurology-focused biotechnology company. Since that time, the Company has:
Received grant funding for a Traumatic Brain Injury collaboration with Banyan Biomarkers from Brewer Sports International;
Recruited seasoned neurology executive Mark Benedyk, PhD to advise the company on strategy and business development efforts;
Received positive feedback on the Company's updated business plan from investors who attended the Company's presentation at the National Investment Banking Association conference in Las Vegas, NV on December 1st, 2011.

"Amarantus has made good progress since the announcement of the Company's expanded corporate strategy, and management will work diligently to cause this trend will continue into 2012," said Gerald Commissiong, Amarantus' newly appointed President and CEO. "We will continue to focus our efforts on securing additional corporate partnerships, improving our pipeline and adding seasoned neurology-focused executives to the executive team in order to diligently build shareholder value and improve the standard of care for patients."
Amarantus believes that it has a unique opportunity to effect meaningful improvements in the treatment of Parkinson's disease for millions of patients worldwide. The Company expects to release additional results to the marketplace from its lead program for Parkinson's disease in the first half of 2012.

About MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor)
MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor) is a protein that corrects protein misfolding, one of the major causes of apoptosis (cell death). This property provides a compelling rationale for the research and development of MANF-based products as therapeutics for human disease. The lead MANF product development effort is centered on a therapy for Parkinson's disease, currently funded by a research grant from the Michael J. Fox Foundation for Parkinson's Research. The Company also owns an inventory of 88 cell lines referred to as "PhenoGuard Cell Lines." MANF was the first therapeutic protein discovered from a PhenoGuard Cell Line. It is anticipated that additional therapeutic proteins useful for various therapeutic approaches to the Central Nervous System will be identified from the Company's inventory of PhenoGuard Cell Lines.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.

Investor Relations Contact:

Seraphim strategies

Lou Levenstein

www.seraphimstrategies.com
www.tomorrowsbluechips.com
727-489-9939

Powered by EIN Presswire